Neuroone Medical Technologies Corp
NASDAQ:NMTC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Neuroone Medical Technologies Corp
NASDAQ:NMTC
|
US |
|
Paycom Software Inc
NYSE:PAYC
|
US |
|
Indusind Bank Ltd
NSE:INDUSINDBK
|
IN |
|
Industrial Investment Trust Ltd
NSE:IITL
|
IN |
|
S
|
Shenzhen Huakong Seg Co Ltd
SZSE:000068
|
CN |
|
PHX Energy Services Corp
TSX:PHX
|
CA |
|
GoTo Gojek Tokopedia PT Tbk
IDX:GOTO
|
ID |
|
S
|
Sama Aluminium Co Ltd
KRX:006110
|
KR |
|
V
|
Verbio SE
SWB:VBK
|
DE |
|
B
|
Bajaj Housing Finance Ltd
NSE:BAJAJHFL
|
IN |
|
Coastal Carolina Bancshares Inc
OTC:CCNB
|
US |
|
Carisma Therapeutics Inc
NASDAQ:CARM
|
US |
|
Shinkin Central Bank
TSE:8421
|
JP |
Neuroone Medical Technologies Corp
NeuroOne Medical Technologies Corp. operates as a medical technology company. The company is headquartered in Eden Prairie, Minnesota and currently employs 11 full-time employees. The company went IPO on 2012-11-09. The firm is focused on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, spinal cord stimulation, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. The company also investigating the applications of its technology associated with artificial intelligence. The company develops its cortical, sheet and depth electrode technology to provides solutions for diagnosis through cEEG recording and sEEG recording and treatment through brain stimulation and ablation. Its commercialized product, Evo sEEG electrode technology records, monitors and stimulates electrical signals at the subsurface level of the brain.
NeuroOne Medical Technologies Corp. operates as a medical technology company. The company is headquartered in Eden Prairie, Minnesota and currently employs 11 full-time employees. The company went IPO on 2012-11-09. The firm is focused on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, spinal cord stimulation, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. The company also investigating the applications of its technology associated with artificial intelligence. The company develops its cortical, sheet and depth electrode technology to provides solutions for diagnosis through cEEG recording and sEEG recording and treatment through brain stimulation and ablation. Its commercialized product, Evo sEEG electrode technology records, monitors and stimulates electrical signals at the subsurface level of the brain.
Revenue Growth: Product revenue was $2.9 million for Q1 2026, up 5.5% sequentially but down from $3.3 million last year, as expected after the initial stocking order in Q1 2025.
2026 Guidance: Management projects at least $10.5 million in revenue for fiscal 2026, representing a minimum 17% increase over 2025.
Gross Margin Expansion: Product gross profit margin improved to 54.2% from 38.9% year-over-year.
Clinical Adoption: The OneRF brain ablation system saw accelerated adoption, with nearly half of all procedures since launch occurring in Q1 2026.
Trigeminal Nerve Launch: Initial limited launch saw 9 patients treated across 3 centers, all reporting pain relief; discussions for potential licensing ongoing.
Operating Expenses: SG&A expected to remain flat, while R&D may fluctuate with accelerated project timelines.
Cash & Funding: Cash and equivalents stood at $3.6 million at quarter end, with management stating funding is secured through fiscal 2026.
